Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China; Department of Toxicology Laboratory, Xinjiang Institute of Traditional Uyghur Medicine, Urumqi 830049, China.
Department of Toxicology Laboratory, Xinjiang Institute of Traditional Uyghur Medicine, Urumqi 830049, China; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Chin J Nat Med. 2020 Feb;18(2):123-137. doi: 10.1016/S1875-5364(20)30013-3.
Fructus Psoraleae, which is commonly consumed for the treatment of osteoporosis, bone fracture, and leucoderma, induces liver injury. This study investigated the pathogenesis of the ethanol extract of Fructus Psoraleae (EEFP)-induced liver injury in rats. EEFP (1.35, 1.80, and 2.25 g·kg) was administrated to Sprague Dawley (SD) rats for 30 d. We measured liver chemistries, histopathology, and quantitative isobaric tags for relative and absolute quantitation (iTRAQ)-based protein profiling. EEFP demonstrated parameters suggestive of liver injury with changes in bile secretion, bile flow rate, and liver histopathology. iTRAQ analysis showed that a total of 4042 proteins were expressed in liver tissues of EEFP-treated and untreated rats. Among these proteins, 81 were upregulated and 32 were downregulated in the treatment group. KEGG pathway analysis showed that the drug metabolic pathways of cytochrome P450, glutathione metabolism, glycerolipid metabolism, and bile secretion were enriched with differentially expressed proteins. The expression of key proteins related to the farnesoid X receptor (FXR), i.e., the peroxisome proliferators-activated receptor alpha (PPAR-α), were downregulated, and multidrug resistance-associated protein 3 (MRP3) was upregulated in the EEFP-treated rats. Our results provide evidence that EEFP may induce hepatotoxicity through various pathways. Furthermore, our study demonstrates changes in protein regulation using iTRAQ quantitative proteomics analysis.
补骨脂,常用于治疗骨质疏松症、骨折和白癜风,可导致肝损伤。本研究探讨了补骨脂乙醇提取物(EEFP)诱导大鼠肝损伤的发病机制。EEFP(1.35、1.80 和 2.25 g·kg)连续 30 天给 Sprague Dawley(SD)大鼠灌胃。我们检测了肝生化、组织病理学和基于定量同位素标记相对和绝对定量(iTRAQ)的蛋白质谱。EEFP 显示出与胆汁分泌、胆汁流速和肝组织病理学变化有关的肝损伤参数。iTRAQ 分析显示,EEFP 处理和未处理大鼠的肝组织中表达了总共 4042 种蛋白质。在这些蛋白质中,有 81 种在治疗组中上调,32 种下调。KEGG 通路分析表明,细胞色素 P450、谷胱甘肽代谢、甘油脂代谢和胆汁分泌的药物代谢途径富含差异表达蛋白。与法尼醇 X 受体(FXR)相关的关键蛋白,即过氧化物酶体增殖物激活受体α(PPAR-α)的表达下调,多药耐药相关蛋白 3(MRP3)在 EEFP 处理的大鼠中上调。我们的结果提供了证据表明 EEFP 可能通过多种途径引起肝毒性。此外,我们的研究通过 iTRAQ 定量蛋白质组学分析证明了蛋白质调节的变化。